Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Taxes (2017 - 2025)

Protagonist Therapeutics' Change in Taxes history spans 8 years, with the latest figure at -$1.9 million for Q2 2025.

  • For Q2 2025, Change in Taxes fell 179.44% year-over-year to -$1.9 million; the TTM value through Dec 2025 reached -$2.7 million, down 200.0%, while the annual FY2025 figure was -$2.7 million, 200.0% down from the prior year.
  • Change in Taxes for Q2 2025 was -$1.9 million at Protagonist Therapeutics, down from -$800000.0 in the prior quarter.
  • Across five years, Change in Taxes topped out at $3.3 million in Q1 2024 and bottomed at -$1.9 million in Q2 2025.
  • The 4-year median for Change in Taxes is $33000.0 (2022), against an average of $164363.6.
  • The largest annual shift saw Change in Taxes surged 363.58% in 2021 before it tumbled 179.44% in 2025.
  • A 4-year view of Change in Taxes shows it stood at $921000.0 in 2021, then tumbled by 96.42% to $33000.0 in 2022, then soared by 4869.7% to $1.6 million in 2024, then crashed by 215.18% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Change in Taxes are -$1.9 million (Q2 2025), -$800000.0 (Q1 2025), and $1.6 million (Q4 2024).